Nov 3, 2022 7:30 am EDT Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Oct 19, 2022 7:30 am EDT Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Oct 4, 2022 7:30 am EDT Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Sep 22, 2022 7:30 am EDT Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
Sep 13, 2022 7:30 am EDT Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
May 19, 2022 7:30 am EDT Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
